Pds Biotechnology Corp (PDSB)
$3.88
Performance
- $3.85$4.05$3.88
0.77%
Downside
Day's Volatility :4.82%
Upside
4.08%
- $2.53$6.85$3.88
34.79%
Downside
52 Weeks Volatility :63.07%
Upside
43.36%
Returns
| Period | Pds Biotechnology Corp | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 20.49% | 6.5% | 0.0% |
6 Months | -28.23% | 7.1% | 0.0% |
1 Year | -23.5% | 9.8% | 0.0% |
3 Years | -58.0% | 14.2% | -20.2% |
Highlights
Market Capitalization | 138.1M |
Book Value | $1.01 |
Earnings Per Share (EPS) | -1.37 |
Wall Street Target Price | 12.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -39.76% |
Return On Equity TTM | -112.25% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -43.7M |
Diluted Eps TTM | -1.37 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.32 |
EPS Estimate Next Year | -1.23 |
EPS Estimate Current Quarter | -0.37 |
EPS Estimate Next Quarter | -0.36 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 209.28%
Technicals Summary
Sell
Neutral
Buy
Pds Biotechnology Corp is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Pds Biotechnology Corp | 29.61% | -28.23% | -23.5% | -58.0% | -31.6% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Pds Biotechnology Corp | NA | NA | NA | -1.32 | -1.12 | -0.4 | NA | 1.01 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Pds Biotechnology Corp | Buy | $138.1M | -31.6% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Pds Biotechnology Corp
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 85.1%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 244.5%
Institutional Holdings
BlackRock Inc
5.09%Vanguard Group Inc
4.33%Geode Capital Management, LLC
1.78%State Street Corporation
1.52%Integrys Wealth Advisors LLC
0.98%Renaissance Technologies Corp
0.97%
Company Information
pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati
Organization | Pds Biotechnology Corp |
Employees | 25 |
CEO | Dr. Frank K. Bedu-Addo Ph.D. |
Industry | Biotechnology |
Discover More
A Spac I Acquisition Corp
$3.88
-1.52%
Keyarch Acquisition Corp
$3.88
-1.52%
Connexa Sports Technologies Inc
$3.88
-1.52%
Us Value Etf
$3.88
-1.52%
First Wave Biopharma Inc
$3.88
-1.52%
Global X Msci Next Emerging
$3.88
-1.52%
Fat Projects Acquisition Corp
$3.88
-1.52%
Capital Link Global Fintech
$3.88
-1.52%
Applied Uv Inc
$3.88
-1.52%